Global T-Cell Immunotherapy Pipeline Analysis, 2016

  • ID: 4085077
  • Report
  • Region: Global
  • 309 pages
  • P&S Market Research
1 of 3
Pipeline Overview
T-cell immunotherapy mainly consists of T-cell receptor (TCR), Tumor-infiltrating lymphocytes (TILs) and Chimeric antigen receptors (CAR) T-cell therapy. TCR is a complex integral membrane protein that activates T-cells in response to an antigen. Major histocompatibility complex (MHC) molecules activates TCR by the presence of an antigen. The activation of TCR initiates positive and negative cascades that leads to cellular proliferation, cytokine production, cellular differentiation, and/or activation of induced cell death. These signaling positive and negative cascades regulate T-cell development, homeostasis, activation, acquisition of effector’s functions and apoptosis.

TILs, defined by NCI, the U.S. federal government's principal agency for cancer research and training, as a preparation of cells consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis. In vitro, TILs are isolated from tumor tissue and cultured with lymphokines such as interleukin-2. The therapeutic TILs are then infused into patients, where after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression. The use of therapeutic TILs is considered as an adoptive immunotherapy.

The high prevalence of cancer and increased safety and efficacy across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer as it has several advantages over conventional therapies such as very low or no side effects and high specificity.

T Cell Immunotherapy Pipeline Analysis

Pipeline Analysis
The T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. There are 16 drug candidates in Phase II stage of development, 36 in Phase I, and seven in Phase 0. Two drug candidates have been filed for Investigational New Drug (IND) application, and there are 78 drugs in Pre-clinical and Discovery stage.

NY-ESO-1 is under Phase II stage of development by Kite Pharmaceuticals Inc. for the treatment of solid tumors including, but not limited to sarcoma, bladder cancer, esophageal carcinoma, non-small cell lung cancer, breast carcinoma, ovarian carcinoma, prostate carcinoma, multiple myeloma, hepatocellular carcinoma and melanoma. The therapeutic candidate targets NY-ESO-1 antigen and being produced by using Engineered Autologous Cell Therapy (eACT) technology. In addition, CART-EGFR, also known as Anti-EFGR-CAR vector-transduced T-cells, is under Phase I/II stage of development by Cellular Biomedicine Group Inc. for the treatment of advanced EGFR-positive solid tumors.

Competitive Landscape
Several companies are involved in T-cell immunotherapy, with their products in different phases. Sorrento Therapeutics, Inc. is developing 21 products based on CAR T-cell therapy. The company is using CAR.TNK technology platform and G-MAB fully human antibody technology for the development of its therapeutic candidates. Novartis Pharmaceuticals has nine products in their pipeline and one drug candidate reached into Phase II clinical stage. Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc., Juno Therapeutics, Inc., Gradalis, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics Plc., Immunocore Limited, and Lion Biotechnologies, Inc.

Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Scope And Methodology
1.1 Research Scope
1.2 Research Methodology And Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Pipeline Outlook
3.1 Overview
3.2 T-Cell Immunotherapy Pipeline Analysis
3.2.1 Pipeline Analysis By Target
3.2.2 Pipeline Analysis By Molecule Type
3.2.3 Pipeline Analysis By Route Of Administration
3.2.4 Pipeline Analysis By Company

4. Global T-Cell Immunotherpay Pipeline Analysis By Phase
4.1 Phase Ii
4.1.1 Tisagenlecleucel-T
4.1.1.1 Clinical Trials
4.1.1.2 Preliminary Results
4.1.1.3 Strategic Development
4.1.1.4 Technology
4.1.1.5 Patent
4.1.2 Cd20
4.1.2.1 Clinical Trials
4.1.2.2 Strategic Development
4.1.2.3 Technology
4.1.3 Axicabtagene Ciloleucel
4.1.3.1 Clinical Trials
4.1.3.2 Interim Results
4.1.3.3 Strategic Development
4.1.3.3.1 Collaboration
4.1.3.3.2 Licensing
4.1.3.3.3 Designation
4.1.3.3.4 Others
4.1.3.4 Technology
4.1.4 Ny-Eso-1
4.1.4.1 Strategic Development
4.1.4.1.1 Collaboration
4.1.4.1.2 Others
4.1.4.2 Technology
4.1.5 Mage A3/A6
4.1.5.1 Strategic Development
4.1.5.1.1 Partnership
4.1.5.1.2 Licensing Agreement
4.1.5.1.3 Others
4.1.5.2 Technology
4.1.6 Jcar015
4.1.6.1 Clinical Trials
4.1.6.2 Strategic Development
4.1.6.2.1 Collaboration
4.1.6.3 Technology
4.1.7 Vigil
4.1.7.1 Clinical Trials
4.1.7.2 Strategic Development
4.1.7.3 Technology
4.1.8 Ebv-Ctl
4.1.8.1 Clinical Trials
4.1.8.2 Clinical Results
4.1.8.3 Strategic Development
4.1.8.3.1 Agreement
4.1.8.3.2 Designation
4.1.8.3.3 Others
4.1.8.4 Technology
4.1.9 Allogeneic Cytomegalovirus (Cmv)-Specific Cytotoxic T Lymphocytes (Ctl)
4.1.9.1 Clinical Trials
4.1.9.2 Clinical Results
4.1.9.3 Strategic Development
4.1.9.4 Technology
4.1.10 Ny-Eso-1 Autologous Engineered Tcr-T-Cells (Engineered Tcr)
4.1.10.1 Clinical Trials
4.1.11 Imcgp100
4.1.11.1 Clinical Trials
4.1.11.2 Technology
4.1.12 Imcgp100 Checkpoint Combination
4.1.12.1 Clinical Trials
4.1.12.2 Strategic Development
4.1.12.3 Technology
4.1.13 Til±Tbi
4.1.13.1 Strategic Development
4.1.13.1.1 Collaboration
4.1.13.1.2 Others
4.1.13.2 Technology
4.1.14 Til + Ipi
4.1.14.1 Strategic Development
4.1.14.1.1 Collaboration
4.1.14.1.2 Others
4.1.14.2 Technology
4.1.15 Til + Keytruda
4.1.15.1 Strategic Development
4.1.15.1.1 Collaboration
4.1.15.1.2 Others
4.1.15.2 Technology
4.1.16 Ln-144
4.1.16.1 Clinical Trials
4.1.16.2 Strategic Development
4.1.16.2.1 Collaboration
4.1.16.2.2 Others
4.1.16.3 Technology
4.2 Phase I
4.2.1 Ln-145
4.2.1.1 Strategic Development
4.2.1.2 Technology
4.2.2 Til + Opdivo
4.2.2.1 Strategic Development
4.2.2.1.1 Collaboration
4.2.2.1.2 Others
4.2.2.2 Technology
4.2.3 Cart-Meso
4.2.3.1 Clinical Trials
4.2.4 Anti-Gd2-Car Engineered T-Cell
4.2.4.1 Clinical Trials
4.2.5 Cd138 Car T Therapy
4.2.5.1 Clinical Trials
4.2.6 Cd19
4.2.6.1 Clinical Trials
4.2.7 Cd30
4.2.7.1 Clinical Trials
4.2.8 Cart-Egfr
4.2.8.1 Clinical Trials
4.2.9 Anti-Cd19-Car
4.2.9.1 Clinical Trials
4.2.10 Cd123 Car
4.2.11 Il13Ra2-Targeted Car T-Cell Therapy
4.2.11.1 Clinical Trials
4.2.12 Anti-Muc1 Car T-Cells
4.2.12.1 Clinical Trials
4.2.13 Anti-Cea Car T
4.2.13.1 Clinical Trials
4.2.14 Cd19 Car Gene Therapy
4.2.14.1 Clinical Trials
4.2.15 Csg-Gpc3
4.2.15.1 Clinical Trials
4.2.16 Csg-Egfr
4.2.16.1 Clinical Trials
4.2.17 Cd19 Specific Car T-Cells
4.2.17.1 Clinical Trials
4.2.18 Kappa Cd28 T-Cells
4.2.18.1 Clinical Trials
4.2.19 Car.Cd30 T-Cells
4.2.19.1 Clinical Trials
4.2.20 Gd2 T-Cells
4.2.20.1 Clinical Trials
4.2.21 Her2-Specific T-Cells
4.2.21.1 Clinical Trials
4.2.22 Nkg2D
4.2.22.1 Clinical Trials
4.2.23 Egfrviii Car
4.2.23.1 Clinical Trials
4.2.24 Human Anti-Cd19 Heme Malignancies
4.2.24.1 Strategic Development
4.2.24.2 Technology
4.2.25 Mage A3
4.2.25.1 Technology
4.2.26 Hpv-16 E6
4.2.26.1 Technology
4.2.27 Anti-Cea 2Nd Generation Designer T-Cell
4.2.27.1 Clinical Trials
4.2.28 Anti-Psma Designer T-Cell
4.2.28.1 Clinical Trials
4.2.29 Jcar014
4.2.29.1 Clinical Trials
4.2.29.2 Results
4.2.29.3 Strategic Development
4.2.29.4 Technology
4.2.30 Jcar016
4.2.30.1 Clinical Trials
4.2.30.2 Preliminary Results
4.2.30.3 Strategic Development
4.2.30.3.1 Collaboration
4.2.30.4 Designation
4.2.30.5 Technology
4.2.31 Jcar017
4.2.31.1 Clinical Trials
4.2.31.2 Preliminary Results
4.2.31.3 Strategic Development
4.2.31.3.1 Collaboration
4.2.31.4 Designation
4.2.31.5 Technology
4.2.32 Jcar018
4.2.32.1 Clinical Trials
4.2.32.2 Preliminary Results
4.2.32.3 Strategic Development
4.2.32.3.1 Collaboration
4.2.32.3.2 Others
4.2.32.4 Technology
4.2.33 Jcar023
4.2.33.1 Clinical Trials
4.2.33.2 Strategic Development
4.2.33.2.1 Collaboration
4.2.33.2.2 Others
4.2.33.3 Technology
4.2.34 B-Cell Malignancies Car T Programme
4.2.34.1 Clinical Trials
4.2.34.2 Clinical Results
4.2.34.3 Strategic Development
4.2.34.3.1 Collaboration
4.2.34.4 Technology
4.2.35 Wilms Tumor 1 (Wt1)-Targeted Ctls
4.2.35.1 Clinical Trials
4.2.36 Mage-A10 Tcr
4.2.36.1 Clinical Trials
4.3 Phase 0
4.3.1 Cart22 Therapy
4.3.1.1 Clinical Trials
4.3.2 Cart-Egfrviii T Therapy
4.3.2.1 Clinical Trials
4.3.3 Rna Cart123 Therapy
4.3.3.1 Clinical Trials
4.3.4 Cart-Bcma Therapy
4.3.4.1 Clinical Trials
4.3.5 Cmet Rna Car T Therapy
4.3.5.1 Clinical Trials
4.3.6 Rna Anti-Cd19 Car T Therapy
4.3.6.1 Clinical Trials
4.3.7 Hucart19 Therapy
4.3.7.1 Clinical Trials
4.4 Ind Filed
4.4.1 Ucart19
4.4.1.1 Strategic Development
4.4.1.1.1 Collaboration
4.4.1.1.2 Others
4.4.1.2 Technology
4.4.2 Kite-718
4.4.2.1 Technology
4.5 Pre-Clinical
4.5.1 Bpx-401
4.5.2 Bpx-601
4.5.2.1 Strategic Development
4.5.3 P-Bcma-101
4.5.3.1 Technology
4.5.4 P-Psma-101
4.5.4.1 Technology
4.5.5 Car T-Cells (Cd19)
4.5.6 Car T-Cell (Cd33-Cd123)
4.5.7 Car T-Cells With Tilt Virus
4.5.8 Bb2121
4.5.9 Csg-002
4.5.10 Csg-Cd19
4.5.11 Csg-Meso
4.5.12 Csg-005
4.5.13 Csg-Gd2
4.5.14 Csg-Cd19
4.5.15 Psca T-Cells
4.5.16 Muc1 T-Cells
4.5.17 Ucart123
4.5.17.1 Strategic Development
4.5.17.2 Technology
4.5.18 Nkp30
4.5.19 B7H6
4.5.20 T3 (Allogeneic)
4.5.21 Cik-Car.Cd19
4.5.22 Cik-Car.Cd33
4.5.23 Cik-Car.Psma
4.5.24 Amgen Multi-Target Car T Program
4.5.25 Hpv-16 E7
4.5.25.1 Technology
4.5.26 Ssx2
4.5.26.1 Technology
4.5.27 Kras
4.5.27.1 Strategic Development
4.5.27.2 Technology
4.5.28 Neo Antigens
4.5.28.1 Technology
4.5.29 Kite-585
4.5.29.1 Technology
4.5.30 Kite-796
4.5.30.1 Technology
4.5.31 Car-Cd44V6
4.5.32 Pdl1.Tank
4.5.33 Gd3
4.5.34 Il13R
4.5.35 C-Kit
4.5.36 Ror1.Tank
4.5.37 Her2.Tank
4.5.38 Cd19 Fully Human Scfv Car
4.5.39 Jcar020
4.5.40 Cd19 Armored Car
4.5.41 Ror-1 Car
4.5.42 Myeloid Malignancies Car T Program
4.5.43 Car And Designer Cytokine Controlled T-Cell
4.5.44 Solid Tumors Car T Programme
4.5.45 Off-The-Shelf T-Cells Car T Programme
4.5.46 Nk Cells Car T Program
4.5.47 Gvhd Therapies
4.5.48 Tcr T-Cells
4.5.49 Sleeping Beauty Tcr
4.5.49.1 Strategic Development
4.5.49.2 Technology
4.5.50 Sleeping Beauty Tcr And Cytokine
4.5.50.1 Strategic Development
4.5.50.2 Technology
4.5.51 Car Mrna Engineered T-Cells
4.5.52 Afp Tcr
4.5.52.1 Strategic Development
4.5.52.2 Technology
4.5.53 Mage-A4
4.5.53.1 Strategic Development
4.5.53.2 Technology
4.5.54 Imcgp100 Smi Combination
4.5.55 Internal Program
4.5.56 Immtac Development Program
4.5.57 Anti-Cd123 Car T Program
4.5.57.1 Technology
4.5.58 Anti-Cd38 Car T-Cells
4.5.58.1 Technology
4.5.59 Til Therapy For Glioblastoma
4.5.59.1 Strategic Development
4.5.60 Til Therapy For Pancreatic Cancer
4.5.60.1 Strategic Development
4.6 Discovery
4.6.1 Ucart22
4.6.1.1 Technology
4.6.1.2 Patent
4.6.2 Ucart38
4.6.2.1 Technology
4.6.3 Ucartcs1
4.6.3.1 Technology
4.6.4 Car T Programme
4.6.4.1 Technology
4.6.5 Procar-Nk Cell Therapy
4.6.5.1 Technology
4.6.6 Crispr-Cas9-Based Therapies Using Chimeric Antigen Receptor T-Cells Program
4.6.6.1 Strategic Development
4.6.6.2 Technology
4.6.7 Solid And Hematologic Tumour Targets Car T Program
4.6.7.1 Technology
4.6.8 Cart Programme
4.6.8.1 Technology
4.6.9 Cd123.Tnk
4.6.9.1 Strategic Development
4.6.9.2 Technology
4.6.10 Egfrviii.Tnk
4.6.10.1 Strategic Development
4.6.10.2 Technology
4.6.11 Epha3.Tnk
4.6.11.1 Strategic Development
4.6.11.2 Technology
4.6.12 L1Cam.Tnk
4.6.12.1 Technology
4.6.13 Cspg4.Tnk
4.6.13.1 Strategic Development
4.6.13.2 Technology
4.6.14 Bcma.Tnk
4.6.14.1 Strategic Development
4.6.14.2 Technology
4.6.15 Cs1.Tnk
4.6.15.1 Strategic Development
4.6.15.2 Technology
4.6.16 Cd19.Tnk
4.6.16.1 Strategic Development
4.6.16.2 Technology
4.6.17 Cd22.Tnk
4.6.17.1 Strategic Development
4.6.17.2 Technology
4.6.18 Psma And Psca.Tnk
4.6.18.1 Strategic Development
4.6.18.2 Technology

5. Swot Analysis Of T-Cell Immunotherapy Pipeline

6. Company Profiles And Strategic Developments
6.1 Key Company Profiles
6.1.1 Novartis Ag
6.1.1.1 Business Overview
6.1.1.2 Product And Service Offerings
6.1.2 Cellular Biomedicine Group, Inc.
6.1.2.1 Business Overview
6.1.2.2 Product And Service Offerings
6.1.3 Kite Pharmaceuticals Inc.
6.1.3.1 Business Overview
6.1.3.2 Product And Service Offerings
6.1.4 Juno Therapeutics, Inc.
6.1.4.1 Business Overview
6.1.4.2 Product And Service Offerings
6.1.5 Gradalis, Inc.
6.1.5.1 Business Overview
6.1.5.2 Product And Service Offerings
6.1.6 Atara Biotherapeutics, Inc.
6.1.6.1 Business Overview
6.1.6.2 Product And Service Offerings
6.1.7 Adaptimmune Therapeutics Plc.
6.1.7.1 Business Overview
6.1.7.2 Product And Service Offerings
6.1.8 Immunocore Limited
6.1.8.1 Business Overview
6.1.8.2 Product And Service Offerings
6.1.9 Lion Biotechnologies, Inc.
6.1.9.1 Business Overview
6.1.9.2 Product And Service Offerings

7. Appendix
7.1 List Of Abbreviations

List Of Tables
Table 1: Specific Primary And Secondary Sources Used For This Publication
Table 2: Number Of Worldwide Deaths Due To Different Cancer
Table 3: Global T-Cell Immunotherapy Pipeline Split, By Company (2016)
Table 4: Clinical Trials Of Cart-19
Table 5: Description Of Tisagenlecleucel-T
Table 6: Clinical Trials Of Cd20
Table 7: Description Of Cd20
Table 8: Clinical Trials Of Kte-C19 Car
Table 9: Description Of Axicabtagene Ciloleucel
Table 10: Description Of Ny-Eso-1
Table 11: Description Of Mage A3/A6
Table 12: Clinical Trials Of Jcar015
Table 13: Description Of Jcar015
Table 14: Clinical Trials Of Vigil
Table 15: Description Of Vigil
Table 16: Clinical Trials Of Ebv Specific T-Cells
Table 17: Description Of Ebv-Ctl
Table 18: Clinical Trials Of Allogeneic Cytomegalovirus (Cmv)-Specific Cytotoxic T Lymphocytes (Ctl)
Table 19: Description Of Allogeneic Cytomegalovirus (Cmv)-Specific Cytotoxic T Lymphocytes (Ctl)
Table 20: Clinical Trials Of Ny-Eso-1 Autologous Engineered Tcr-T-Cells (Engineered Tcr)
Table 21: Description Of Ny-Eso-1 Autologous Engineered Tcr-T-Cells (Engineered Tcr)
Table 22: Clinical Trials Of Imcgp100
Table 23: Description Of Imcgp100
Table 24: Clinical Trials Of Imcgp100 Checkpoint Combination
Table 25: Description Of Imcgp100 Checkpoint Combination
Table 26: Description Of Til±Tbi
Table 27: Description Of Til+Ipi
Table 28: Description Of Til+Keytruda
Table 29: Clinical Trials Of Ln-144
Table 30: Description Of Ln-144
Table 31: Description Of Ln-145
Table 32: Description Of Til + Opdivo
Table 33: Clinical Trials Of Cart-Meso
Table 34: Description Of Cart-Meso
Table 35: Clinical Trials Of Anti-Gd2-Car Engineered T-Cells
Table 36: Description Of Anti-Gd2-Car Engineered T-Cells
Table 37: Clinical Trials Of Cd138 Car- T Therapy
Table 38: Description Of Cd138 Car T Therapy
Table 39: Clinical Trials Of Cd19
Table 40: Description Of Cd19
Table 41: Clinical Trials Of Cd30
Table 42: Description Of Cd30
Table 43: Clinical Trials Of Cart-Egfr
Table 44: Description Of Cart-Egfr
Table 45: Clinical Trials Of Anti-Cd19-Car
Table 46: Description Of Anti-Cd19-Car
Table 47: Description Of Cd123-Car
Table 48: Clinical Trials Of Il13R?2-Targeted Car T-Cell Therapy
Table 49: Description Of Il13R?2-Targeted Car T-Cell Therapy
Table 50: Clinical Trials Of Anti-Muc1 Car T-Cells
Table 51: Description Of Anti-Muc1 Car T-Cells
Table 52: Clinical Trials Of Anti-Cea Car T-Cells
Table 53: Description Of Anti-Cea Car T-Cells
Table 54: Clinical Trials Of Cd19 Car Gene Therapy
Table 55: Description Of Cd19 Car Gene Therapy
Table 56: Clinical Trials Of Csg-Gpc3
Table 57: Description Of Csg-Gpc3
Table 58: Clinical Trials Of Csg-Egfr
Table 59: Description Of Csg-Egfr
Table 60: Clinical Trials Of Cd19 Specific Car T-Cells
Table 61: Description Of Cd19 Specific Car T-Cells
Table 62: Clinical Trials Of Kappa Cd28 T-Cells
Table 63: Description Of Kappa Cd28 T-Cells
Table 64: Clinical Trials Of Car.Cd30 T-Cells
Table 65: Description Of Car.Cd30 T-Cells
Table 66: Clinical Trials Of Gd2 T-Cells
Table 67: Description Of Gd2 T-Cells
Table 68: Clinical Trials Of Her2-Specific T-Cells
Table 69: Description Of Her2-Specific T-Cells
Table 70: Clinical Trials Of Nkg2D
Table 71: Description Of Nkg2D
Table 72: Clinical Trials Of Egfrviii Car
Table 73: Description Of Egfrviii Car
Table 74: Description Of Human Anti-Cd19 Heme Malignancies
Table 75: Description Of Mage A3
Table 76: Description Of Hpv-16 E6
Table 77: Clinical Trials Of Anti-Cea 2Nd Generation Designer T-Cells
Table 78: Description Of Anti-Cea 2Nd Generation Designer T-Cells
Table 79: Clinical Trials Of Anti-Psma Designer T-Cells
Table 80: Description Of Anti-Psma Designer T-Cells
Table 81: Clinical Trials Of Jcar014
Table 82: Description Of Jcar014
Table 83: Clinical Trials Of Jcar016
Table 84: Description Of Jcar016
Table 85: Clinical Trials Of Jcar017
Table 86: Description Of Jcar017
Table 87: Clinical Trials Of Jcar018
Table 88: Description Of Jcar018
Table 89: Clinical Trials Of Jcar023
Table 90: Description Of Jcar023
Table 91: Clinical Trials Of B-Cell Malignancies Car T Programme
Table 92: Description Of B-Cell Malignancies Car T Programme
Table 93: Clinical Trials Of Wt1-Sensitized T-Cells
Table 94: Description Of Wilms Tumor 1 (Wt1)-Targeted Ctls
Table 95: Clinical Trials Of Mage-A10 Tcr
Table 96: Description Of Mage-A10 Tcr
Table 97: Clinical Trials Of Cart22
Table 98: Description Of Cart22 Therapy
Table 99: Clinical Trials Of Cart-Egfrviii T Therapy
Table 100: Description Of Cart-Egfrviii T Therapy
Table 101: Clinical Trials Of Rna Cart123 Therapy
Table 102: Description Of Rna Cart123 Therapy
Table 103: Clinical Trials Of Rna Cart-Bcma Therapy
Table 104: Description Of Rna Cart-Bcma Therapy
Table 105: Clinical Trials Of Cmet Rna Car T Therapy
Table 106: Description Of Cmet Rna Car T Therapy
Table 107: Clinical Trials Anti- Cd19 Car T Therapy
Table 108: Description Of Rna Anti- Cd19 Car T Therapy
Table 109: Clinical Trials Of Hucart19 Therapy
Table 110: Description Of Hucart19 Therapy
Table 111: Description Of Ucart19
Table 112: Description Of Kite-718
Table 113: Description Of Bpx-401
Table 114: Description Of Bpx-601
Table 115: Description Of P-Bcma-101
Table 116: Description Of P-Psma-101
Table 117: Description Of Car T-Cells (Cd19)
Table 118: Description Of Car T-Cells (Cd33-Cd123)
Table 119: Description Of Car T-Cells With Tilt Virus
Table 120: Description Of Bb2121
Table 121: Description Of Csg-002
Table 122: Description Of Csg-Cd19
Table 123: Description Of Csg-Meso
Table 124: Description Of Csg-005
Table 125: Description Of Csg-Gd2
Table 126: Description Of Csg-Cd19
Table 127: Description Of Psca T-Cells
Table 128: Description Of Muc1 T-Cells
Table 129: Description Of Ucart123
Table 130: Description Of Nkp30
Table 131: Description Of B7H6
Table 132: Description Of T3 (Allogeneic)
Table 133: Description Of Cik-Car.Cd19
Table 134: Description Of Cik-Car.Cd33
Table 135: Description Of Cik-Car.Psma
Table 136: Description Of Amgen Multi-Target Car T Program
Table 137: Description Of Hpv-16 E7
Table 138: Description Of Ssx2
Table 139: Description Of Kras
Table 140: Description Of Neo Antigens
Table 141: Description Of Kite-585
Table 142: Description Of Kite-796
Table 143: Description Of Car-Cd44V6
Table 144: Description Of Pdl1.Tank
Table 145: Description Of Gd3
Table 146: Description Of Il13R
Table 147: Description Of C-Kit
Table 148: Description Of Ror1.Tank
Table 149: Description Of Her2.Tank
Table 150: Description Of Cd19 Fully Human Scfv Car
Table 151: Description Of Jcar020
Table 152: Description Of Cd19 Armored Car
Table 153: Description Of Ror-1 Car
Table 154: Description Of Myeloid Malignancies Car T Program
Table 155: Description Of Car And Designer Cytokine Controlled T-Cell
Table 156: Description Of Solid Tumors Car T Programme
Table 157: Description Of Off-The-Shelf T-Cells Car T Programme
Table 158: Description Of Nk Cells Car T Programme
Table 159: Description Of Gvhd Therapies
Table 160: Description Of Tcr T-Cells
Table 161: Description Of Sleeping Beauty Tcr
Table 162: Description Of Sleeping Beauty Tcr And Cytokine
Table 163: Description Of Car Mrna Engineered T-Cells
Table 164: Description Of Afp Tcr
Table 165: Description Of Mage-A4
Table 166: Description Of Imcgp100 Smi Combination
Table 167: Description Of Internal Program
Table 168: Description Of Immtac Development Program
Table 169: Description Of Anti-Cd123 Car T Program
Table 170: Description Of Anti-Cd38 Car T-Cells
Table 171: Description Of Til Therapy For Glioblastoma
Table 172: Description Of Til Therapy For Pancreatic Cancer
Table 173: Description Of Ucart22
Table 174: Description Of Ucart38
Table 175: Description Of Ucartcs1
Table 176: Description Of Car T Program
Table 177: Description Of Procar-Nk Cell Therapies
Table 178: Description Of Crispr-Cas9-Based Therapies Using Chimeric Antigen Receptor T-Cells Program
Table 179: Description Of Solid And Hematologic Tumor Targets Car T Program
Table 180: Description Of Cart Programme
Table 181: Description Of Cd123.Tnk
Table 182: Description Of Egfrviii.Tnk
Table 183: Description Of Epha3.Tnk
Table 184: Description Of L1Cam.Tnk
Table 185: Description Of Cspg4.Tnk
Table 186: Description Of Bcma.Tnk
Table 187: Description Of Cs1.Tnk
Table 188: Description Of Cd19.Tnk
Table 189: Description Of Cd22.Tnk
Table 190: Description Of Psma And Psca.Tnk
Table 191: Swot Analysis Of T-Cell Immunotherapy
Table 192: Novartis AG- Key Facts
Table 193: Cellular Biomedicine Group, Inc. - Key Facts
Table 194: Kite Pharmaceuticals Inc. - Key Facts
Table 195: Juno Therapeutics, Inc. - Key Facts
Table 196: Gradalis, Inc. - Key Facts
Table 197: Atara Biotherapeutics, Inc.- Key Facts
Table 198: Adaptimmune Therapeutics Plc. - Key Facts
Table 199: Immunocore Limited - Key Facts
Table 200: Lion Biotechnologies, Inc. - Key Facts

List Of Figures
Fig 1: Global Incidence Of Cancer (2015)
Fig 2: Number Of Products Of T-Cell Immunotherapy Under Development (2016)
Fig 3: Global T-Cell Immunotherapy Pipeline Split, By Target (2016)
Fig 4: Global T-Cell Immunotherapy Pipeline Split, By Molecule Type (2016)
Fig 5: Global T-Cell Immunotherapy Pipeline Split, By Route Of Administration (2016)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll